Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

WIDAPLIK

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

Standard Dose
EQ 2.5MG BASE;1.25MG;20MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview WIDAPLIK is listed in Drugs@FDA under application 219423 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN Form and strength TABLET;ORAL - EQ 2.5MG BASE;1.25MG;20MG Sponsor AZURITY Submission history Latest submission status date: 2025-06-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview WIDAPLIK is listed in Drugs@FDA under application 219423 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN Form and strength TABLET;ORAL - EQ 2.5MG BASE;1.25MG;20MG Sponsor AZURITY Submission history Latest submission status date: 2025-06-05 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.